Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Update

Aspira Women’s Health Inc. (NASDAQ:AWH) saw a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 274,700 shares, a drop of 11.2% from the July 15th total of 309,200 shares. Based on an average daily volume of 114,200 shares, the short-interest ratio is currently 2.4 days. Approximately 2.8% of the company’s stock are short sold.

Institutional Trading of Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its stake in Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,371 shares of the company’s stock after acquiring an additional 53,997 shares during the period. B. Riley Wealth Advisors Inc. owned 1.73% of Aspira Women’s Health worth $732,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 12.19% of the company’s stock.

Aspira Women’s Health Price Performance

AWH opened at $1.06 on Monday. The stock has a market capitalization of $13.20 million, a PE ratio of -0.73 and a beta of 1.54. The firm’s fifty day moving average price is $1.39 and its 200 day moving average price is $2.72. Aspira Women’s Health has a 12-month low of $0.86 and a 12-month high of $6.75.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. The company had revenue of $2.42 million during the quarter, compared to analyst estimates of $2.60 million. During the same period in the prior year, the company earned ($0.28) earnings per share. On average, equities research analysts forecast that Aspira Women’s Health will post -1.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. StockNews.com upgraded shares of Aspira Women’s Health from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th. Alliance Global Partners dropped their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.